血脂康胶囊对冠病血脂达标患者血脂水平的控制研究.pdfVIP

Clinical Study on Maintaining The Lipid Level Reached The Standard In Patients With CHD With Xue Zhi Kang Capsule Speciality: Internal Medicine of Traditional Chinese Medicine Author: Liu Jin Bo Tutor: Pro. Su Wen Ge Abstract Objective: To investigate the clinical effect of maintaining the lipid level reached the standard in patients with CHD and Hyperlipidemia with xue zhi kang capsule.To provide a reference for treatment of this dissease.To explore the advantages and feasibility of treatment of this dissease with xue zhi kang capsule and western medicine treating idiopathic nephrotic syndrome and lay the foundation for further improvement. Methods: Method 60 Cases of premature beat of CHD and Hyperlipidemia ( the lipid level reached the standard after treatment ),and divided into xuezhikang group(20 cases) , simvastatin group(20 cases) and control group(20 cases). At the Premise of continueing the basic treatment of CHD. After a period of drug-eluting(two weeks),Be treated with xuezhikang capsule , simvastatin tablets and control for 2,4 and 6 weeks,then to observe the curative effect. Result: Basic treatment of CHD plus Xuezhikang capsule antianginal effect is more obvious (P＜0.05).The result of maintaining the lipid level reached the standard,The basis of treatment groups after 2 weeks discontinuing lipid-lowering drug,blood lipid levels can be maintained normal (P ＞0.05),but Lipid-lowering drugs are discontinued after 4 （＜ ） weeks,lipid levels is no longer standard P 0.05 ,and Increased antimissily. Xuezhikang oral maintenance dose can maintain the stability of blood lipid levels (P ＞0.05), Xuezhikang maintenance dose and low dose simvastatin can maintai